BMB’s 75th Anniversary Symposium
We are delighted to invite you to the Department’s 75th Anniversary Symposium, taking place on October 24, 2025
Since our founding in 1950 alongside the Faculty of Medicine, our Department has contributed to groundbreaking scientific achievements—from decoding the genetic code to Nobel Prize-winning advances in site-directed mutagenesis. This special event will celebrate our legacy, highlight exciting current research, and offer a look ahead at the future of biochemistry and molecular biology at UBC.
The 75th Anniversary symposium will feature presentations from esteemed alumni, including Dr. Peter Davies (Queens University), Dr. Ruedi Aebersold (ETH Zurich), Dr. David Russell (UT Southwestern), Dr. Marlys Koschinsky (Western University), Dr. Albert Berghuis (McGill University), and Dr. Dustin King (Simon Fraser University) and display of historical items from our department.
You can register under this link: https://event.fourwaves.com/75th-ubc-bmb/pages.
We look forward to celebrating this milestone with you.
PhD Exit Seminar: Karlie Edwards
June 30, 2025 from 2:30 – 3:30 in LSC#3
BMB Research Seminar: Dr. Ben Montpetit
June 19, 2025, from 3:30 PM to 4:30 PM at LSC 3 & Zoom
BMB Teaching and Learning Seminar: Dr. Eden Fussner-Dupas and Dr. Lindsay Rogers
June 2, 2025 from 2:30 PM to 3:30 PM at LSC 3 & Zoom
World’s First Personalized CRISPR Therapy for Genetic Disease Enabled by Groundbreaking Research at BMB
A groundbreaking milestone in genetic medicine has been reached at the Children’s Hospital of Philadelphia, where a baby with a devastating genetic condition received the world’s first personalized CRISPR-based gene therapy. This therapy was uniquely tailored to correct the child’s specific disease-causing mutation.
Crucially, the treatment was delivered using lipid nanoparticles (LNPs) developed by Acuitas Therapeutics—a company co-founded in 2009 by Dr. Pieter Cullis, a professor in our Department of Biochemistry and Molecular Biology (BMB). Dr. Cullis is internationally recognized as a pioneer in LNP research and development. His foundational and translational work in this field laid the essential groundwork for this medical breakthrough.
This landmark success marks a pivotal moment in precision medicine, opening the door to the treatment of many other monogenic rare diseases. The Department proudly congratulates Dr. Cullis for his visionary contributions that continue to shape the future of genetic therapies.
Learn More
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Special Seminar: Dr. Bowen Li
April 22, 2025 at 11AM to 12 PM in CHBE 102
